JPWO2019219851A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019219851A5 JPWO2019219851A5 JP2020561892A JP2020561892A JPWO2019219851A5 JP WO2019219851 A5 JPWO2019219851 A5 JP WO2019219851A5 JP 2020561892 A JP2020561892 A JP 2020561892A JP 2020561892 A JP2020561892 A JP 2020561892A JP WO2019219851 A5 JPWO2019219851 A5 JP WO2019219851A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- administered
- dose
- adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 5
- 241000701161 unidentified adenovirus Species 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 3
- 102000038129 antigens Human genes 0.000 claims 3
- 108091007172 antigens Proteins 0.000 claims 3
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 3
- 238000002255 vaccination Methods 0.000 claims 3
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 2
- 108050006987 Poxvirus Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 241001212582 Ancara Species 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 208000007089 Vaccinia Diseases 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920000023 polynucleotide Polymers 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1807932.7 | 2018-05-16 | ||
| GBGB1807932.7A GB201807932D0 (en) | 2018-05-16 | 2018-05-16 | Compositions and methods for inducing an immune response |
| PCT/EP2019/062694 WO2019219851A1 (fr) | 2018-05-16 | 2019-05-16 | Compositions et procédés pour induire une réponse immunitaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021528367A JP2021528367A (ja) | 2021-10-21 |
| JPWO2019219851A5 true JPWO2019219851A5 (fr) | 2022-05-18 |
Family
ID=62623405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561892A Pending JP2021528367A (ja) | 2018-05-16 | 2019-05-16 | 免疫応答を誘導するための組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210213060A1 (fr) |
| EP (1) | EP3793581A1 (fr) |
| JP (1) | JP2021528367A (fr) |
| KR (1) | KR20210018295A (fr) |
| CN (1) | CN112088012A (fr) |
| AU (1) | AU2019270424A1 (fr) |
| CA (1) | CA3097951A1 (fr) |
| GB (1) | GB201807932D0 (fr) |
| MX (1) | MX2020012150A (fr) |
| SG (1) | SG11202010862VA (fr) |
| WO (1) | WO2019219851A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2023105221A1 (fr) * | 2021-12-07 | 2023-06-15 | Vaccitech (Uk) Limited | Méthodes et compositions d'amplification de vaccin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0203419D0 (en) * | 2002-02-13 | 2002-04-03 | Oxford Biomedica Ltd | Peptide |
| GB201006405D0 (en) * | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
| KR20200087880A (ko) * | 2012-10-28 | 2020-07-21 | 버베리안 노딕 에이/에스 | 강력한 ｔ-세포 및 항체 반응을 위한 ｐｒ13.5 프로모터 |
-
2018
- 2018-05-16 GB GBGB1807932.7A patent/GB201807932D0/en not_active Ceased
-
2019
- 2019-05-16 CN CN201980030633.8A patent/CN112088012A/zh active Pending
- 2019-05-16 US US17/055,056 patent/US20210213060A1/en active Pending
- 2019-05-16 MX MX2020012150A patent/MX2020012150A/es unknown
- 2019-05-16 AU AU2019270424A patent/AU2019270424A1/en active Pending
- 2019-05-16 EP EP19734251.2A patent/EP3793581A1/fr active Pending
- 2019-05-16 CA CA3097951A patent/CA3097951A1/fr active Pending
- 2019-05-16 SG SG11202010862VA patent/SG11202010862VA/en unknown
- 2019-05-16 KR KR1020207036057A patent/KR20210018295A/ko not_active Application Discontinuation
- 2019-05-16 JP JP2020561892A patent/JP2021528367A/ja active Pending
- 2019-05-16 WO PCT/EP2019/062694 patent/WO2019219851A1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2293692A1 (fr) | Procede reactif de vaccination permettant de generer une reponse immunitaire de cellules t cd8 | |
| JP2019526580A5 (fr) | ||
| CA2282300A1 (fr) | Poxvirus recombine destine a une immunisation contre l'antigene associe aux tumeurs muc1 | |
| Haq et al. | Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen | |
| JP2010523138A5 (fr) | ||
| US20210213060A1 (en) | Compositioins for inducing an immune response | |
| JPWO2019219851A5 (fr) | ||
| CA3133971A1 (fr) | Virotherapie oncolytique par rappel heterologue sequentiel | |
| Rittich et al. | Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2 | |
| JPWO2020144615A5 (fr) | ||
| JPWO2021019235A5 (fr) | ||
| JP2023503858A (ja) | ４－１ｂｂｌアジュバント添加した組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）の医学的使用 | |
| AU775973B2 (en) | Methods and reagents for vaccination which generate a CD8 T cell immune response | |
| JPWO2021209897A5 (fr) | ||
| Chamberlain et al. | THE USE OF RECOMBINANT POXVIRUSES AS A PARADIGM FOR THE DEVELOPMENT OF ANTI-CANCER VACCINES |